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Abstract
Background: The antimicrobial activity of Mul-1867, a novel synthetic compound, was tested against 18 bacterial
strains, including clinical isolates and reference strains from culture collections.
Methods: The minimal inhibitory concentration (MICs) and minimal bactericidal concentration (MBCs) were
determined by using the broth macrodilution method. The kinetics of the inhibitory effects of Mul-1867 against
biofilm-growing microorganisms was assessed at time-kill test in vitro against 48-h-old biofilms of Staphylococcus
aureus and Escherichia coli. Transmission electron microscopy analyses was conducted to examine cell disruption.
Results: A comparative assessment of the antimicrobial activities of Mul-1867 and chlorhexidine digluconate (CHG),
used as a control antimicrobial, indicated that Mul-1867 was significantly more effective as a disinfectant than CHG.
Mul-1867 showed potent antimicrobial activities against all the tested bacteria (MIC: 0.03–0.5 μg/mL). Furthermore,
MBC/MIC ratio of Mul-1867 for all tested strains was less than or equal to 4. Time-kill studies showed that treatment
with Mul-1867 (0.05–2 %) reduced bacterial numbers by 2.8–4.8 log10 colony forming units (CFU)/mL within 15–60 s.
Bactericidal activity of Mul-1867 was confirmed by morphological changes revealed by TEM suggested that the killing
of bacteria was the result of membrane disruption.
Conclusion: Overall, these data indicated that Mul-1867 may be a promising antimicrobial for the treatment and
prevention of human infections.
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Background
Microbial infections are one of the main causes of mor-
bidity and mortality. Infectious disease treatments are
associated with challenges including increasing anti-
microbial resistance, drug cytotoxicity, and limited drug
spectrum and these difficulties have instigated novel
antimicrobial drug development [1–3]. Antibiotic and
antiseptic resistance have partly emerged by the preva-
lence of bacteria in the form of biofilms, which enable
microorganisms to survive antibiotic concentrations that
are 1000 times higher than the minimal inhibitory concen-
tration (MIC) [4–6]. Previous studies have attributed the
high antibiotic tolerance of biofilms to a lipid-composed
film that is present on the outer surface and due to
the presence of extracellular polymeric substances in-
side microbial community [7, 8]. Biofilms have also
been associated with a variety of human infections
and are known to be poor responders to antibiotic
and antiseptic therapy [9–11].
Topical antimicrobial agents are routinely used in
various branches of medicine such as dentistry, otolaryn-
gology, surgery and gynecology [12–16]. They are also
used to reduce nosocomial infections and are particularly
useful in preventing infections in intensive care unit pa-
tients [17–19]. Chlorhexidine gluconate (CHG) is one of
the most widely used antimicrobial agents due to its broad
spectrum of antimicrobial action and compatibility with
several types of materials [20–23]. The above-mentioned
properties of CHG have enabled its incorporation in
numerous pharmaceutical and medical devices [24, 25].
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Furthermore, the emergence of chlorhexidine-resistant
microorganisms, for example Klebsiella pneumoniae and
Staphylococcus aureus have also posed treatment chal-
lenges [26, 27]. Thus, there is a critical need for the devel-
opment of new antimicrobials that have a broad-spectrum
of antimicrobial activity and that can be effectively used to
treat resistant bacteria.
In this study, we describe a potential new antimicrobial
compound called Mul-1867 [poly-N1-hydrazino(imino)-
methyl-1,6-hexanediamine; Fig. 1].
The objective of this study was to assess the in vitro
antibacterial activity of Mul-1867. Furthermore, the com-
parative antimicrobial efficacies of Mul-1867 and CHG
against established 48-h-old biofilms were also assessed.
Methods
Antimicrobial agents
Mul-1867 was synthesized in TGV-Laboratories Inc.
(NJ, USA). CHG solution (20 % in H2O) was obtained
from Sigma Chemical Co. (St. Louis, Mo.). Mul-1867
and CHG were diluted with sterile distilled water on the
day of use.
Bacterial strains
Bacillus cereus VT-289, Enterococcus faecalis VT-72, E.
faecalis VT-693, Escherischia coli VT-1402, K.pneumoniae
VT-1367, Neisseria subflavaVT-455, Pseudomonas aerugi-
nosa VT-177, Salmonella enterica VT-191, S. аureus
MSSA VT 961, S. aureus MRSA VT −234, Streptococcus
epidermidis VT-432, S. mitis VT-842, and S. pyogenes VT
59, S. epidermidis VT 908 were obtained from a private
collection (provided by Dr. V. Tetz, Institute Of Human
Microbiology, LLC). Control strains included E. faecalis
ATCC 29212, E. coli ATCC 25922, P. aeruginosa ATCC
27853, and S. aureus ATCC 29213 and were purchased
from American Type Culture Collection (ATCC). All bac-
terial strains were subcultured from freezer stocks onto
brain heart infusion agar plates (BHI; Difco, Detroit,
MI, USA) and incubated at 37 °C overnight. All sub-
sequent liquid subcultures were derived from colonies
isolated from these plates and were grown in Luria-
Bertani broth medium (LB, Oxoid).
Antimicrobial susceptibility of planktonic bacteria
The MICs and minimal bactericidal concentrations
(MBCs) for antimicrobials were determined by using the
broth macrodilution method in accordance with the
Clinical and Laboratory Standards Institute guidelines
[28, 29]. A standard inoculum of 5 × 105 CFU/mL was
used. Serial 2-fold dilutions of the antimicrobials were
prepared in cation-adjusted Mueller-Hinton broth. The
MIC was defined as the lowest concentration of anti-
biotic that completely inhibited visible growth. The
MBC was defined as the lowest antimicrobial concentra-
tion that killed ≥ 99.9 % of the initial bacterial count (≥3
log10 CFU/mL) in 24 h.
Kinetics of Mul-1867 and CHG activity against biofilms
To determine the minimum concentration and exposure
time required by Mul-1867 and CHG to kill biofilms, we
performed a time-kill test in vitro and assessed the activ-
ity of serially diluted Mul-1867 and CHG against the
biofilms of S. aureus ATCC 29213 and E. coli ATCC
25922. This method was developed for determining MIC
of antibiotics against planktonic growing cells by Ernst
et al. [30]. We used a modified protocol of this method
to study the antimicrobial activities of Mul-1867 and
CHG against preformed biofilms. Briefly, all bacterial
cultures were grown overnight as liquid cultures and
200 μL inoculum (5 × 105 CFU/mL) for each strain was
transferred to a 96-well microtiter plates (Sarstedt,
Numbrecht, Germany). The plates were then incubated
for 48 h at 37 °C. The wells proximal to the plate frame
were filled with medium only and were used as negative
controls for growth. After incubation, the growth
medium was removed from the wells without disrupting
the integrity of the biofilms. The formed biofilms were
then gently washed three times with PBS to remove
nonadherent cells. Next, 200 μL of Mul-1867 or CHG
diluted in sterile distilled water were added in the appro-
priate wells for 15, 30, or 60 s. Untreated biofilms were
used as negative controls for each isolate at each time
point. After the exposure, well contents were aspirated
again and to prevent antimicrobial carry-over each well
was washed three times with deionized water. Biofilms
were scraped thoroughly, with particular attention to
Fig. 1 Chemical structure of Mul-1867, n = 1–20
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well edges. The well contents were aspirated again, then
placed in 1 mL of PBS and the total CFU number was
determined by serial dilution method and plating on ap-
propriate media. Data were converted to a log10 scale
and compared to 1 x 108 CFU untreated 48-h-old bio-
films. All assays included at minimum 2 replicates and
were repeated in 3 independent experiments.
Transmission electron microscopy
Transmission electron microscopy analyses was con-
ducted to examine cell disruption. The assay was per-
formed using planktonic growing S. aureus ATCC
29213. Bacteria were centrifuged 3000 g (Eppendorf
5415 C centrifuge; Eppendorf Geratgebau GmbH, Ham-
burg, Germany) and suspended in isotonic phosphate
buffer (0.15 M, pH 7.2). Mul-1867 was added to the bac-
terial suspension to a final concentration of 0.5 %. Tubes
were shacked for 30 s at 22 °C and bacteria were har-
vested by 10 min of centrifugation at 3000 g. After treat-
ment, cells were observed under a transmitting electron
microscope (Carl Zeiss, LIBRA 120) at 80 kV [31, 32].
Evaluation of Mul-1867 effect on membrane integrity
The assay was performed using planktonic growing S.
aureus ATCC 29213 and E. coli ATCC 25922. Mul-1867
was added at final concentration 0.5 % to a standard in-
oculum of 5 × 107 CFU/mL. Tubes were shacked for
30 s at 22 °C and bacteria were harvested by 10 min of
centrifugation at 3000 g (Eppendorf 5415 C centrifuge).
DNA was extracted from the supernatant solution with
QIAamp DNA Mini Kit (Qiagen, GmbH), following the
manufacturer’s instructions. DNA amount was deter-
mined by optical density at 260 nm (OD260) using an
Eppendorf BioPhotometer 6131 (Hamburg, Germany).
To control the purity of the DNA, only samples with an
OD260/OD280 ratio of 1.8–2.0 were used for subse-
quent analysis. A background value of OD at 320 nm
was subtracted from the measured values of OD260
and OD280. Measurements were conducted at room
temperature.
Statistical analysis
All experiments were performed in triplicates. Results
are provided as mean ± standard deviation. All statistical
analyses were performed using the statistics package
Statistica for Windows (version 5.0). A p-value of < 0.05
was considered statistically significant.
Results
Antibacterial activity
The MICs and MBCs of Mul-1867 against 18 bacterial
strains are shown in Table 1.
Mul-1867 inhibited the growth of all the microorgan-
isms tested, with MIC values ranging from 0.03 to
0.5 mg/L. The MIC values of Mul-1867 against bacteria
were considerably lower than those of CHG. Notably,
Mul-1867 antibacterial activity was 2 to 256 times higher
than that of CHG which MIC values ranging from 1 to
32 mg/L. The most resistant test organisms, B. cereus
and S. enterica, were killed by 2 mg/L of Mul-1867. In
contrast, list the most resistant organisms to CHG were
K. pneumonia and P.aeruginosa with MIC 32 mg/L. The
MBCs values of Mul-1867 were lower than 0.5 mg/L for
14 strains, and the MBC values for the other 4 strains
ranged from 0.5 to 2 mg/L. After Mul-1867 treatment,
the MBC/MIC ratios of 86 % microbial strains were < 4,
whereas, those of the remaining 14 % of cultures were 4.
Thus Mul-1867 inhibited bacterial growth of all bacterial
strains in a bactericidal manner (MBC/MIC ratio ≤ 4).
After CHG treatment, the MBC/MIC ratios were < 4 for
60 % strains and the ratios ranged from 4 to 12 for the
remaining 40 % strains indicating that CHG displays
bactericidal and bacteriostatic effects. No Mul-1867-
resistant strain was identified among the clinical isolates.
Kinetics of inhibitory effect of Mul-1867 against
bacterial biofilms
The kinetics of the inhibitory effects of Mul-1867 against
biofilm-growing microorganisms are summarized in
Fig. 2 (p < 0.005).
Table 1 In vitro antibacterial activity of Mul-1867
Organism Mul-1867 (mg/L) CHG (mg/L)
MIC MBC MIC MBC
Gram-positive bacteria
B. cereus VT-289 0.5 2 1.0 2.0
E. faecalis ATCC 29212 0.03 0.06 2.0 8.0
E. faecalis VT-72 0.06 0.125 4.0 16.0
E. faecalis VT-693 0.06 0.06 2.0 16.0
S. aureus АТСС 29213 0.125 0.15 2.0 2.0
S. аureus MSSA VT-961 0.06 0.125 2.0 2.0
S. aureus MRSA VT-234 0.06 0.125 4.0 4.0
S. epidermidis VT-432 0.06 0.125 2.0 16.0
S. epidermidis VT 908 0.25 0.5 2.0 16.0
S. mitis VT-842 0.06 0.06 4.0 64.0
S. pyogenes VT 59 0.125 0.125 8.0 16.0
Gram-negative bacteria
E. coli АТСС 25922 0.25 0.25 2.0 16.0
E. coli VT-1402 0.06 0.06 16.0 32.0
K. pneumoniae VT-1367 0.125 0.25 32.0 32.0
N. subflava VT-455 0.125 0.25 8.0 8.0
P. aeruginosae ATCC 27853 1.0 1.0 32.0 64.0
P. aeruginosae VT-177 0.125 0.25 32.0 32.0
S. enterica VT-191 0.5 2 16.0 32.0
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Mul-1867 or CHG displayed a concentration-dependent
bactericidal activity against 48-h-old biofilms and exhib-
ited a significant reduction in the number of viable bac-
teria within biofilms for all periods of exposure. There was
a dose-dependent decrease in CFU numbers with increase
in antibiotic exposure time for antimicrobials at concen-
trations of 0.05 % or higher. Our study demonstrated that
both antiseptics possess microbicidal activity that can be
effective within contact times ranging from 15 to 60 s.
The number of viable cells dropped dramatically after
15 s, after which cell death continued at a much slower
rate. The bactericidal efficiency of Mul-1867 was higher
than that of CHG at the same concentrations. We found
that Mul-1867 was approximately up to 20 times more ef-
ficient than CHG at all time points assessed.
Mode of action of Mul-1867 on bacteria
The untreated S.aureus cells, prepared for TEM micro-
graphs shown a normal cell shape with an undamaged
structure of the inner membrane (Fig. 3a). In all cases
bacteria appeared to be lysed after Mul-1867 treatment
(Fig. 3b).
The images of S.aureus strains show that treated bac-
teria are collapsed and their cell walls are degraded. The
black arrows point out the dead cells with damaged
membranes accompanied by the leakage of intracellular
components.
Among the indicators of membrane damage, an in-
creased DNA concentration from lysed bacteria in the






Fig. 2 In vitro time-kill assessment of the bactericidal activity of Mul-1867 and CHG against bacterial biofilms. Kill curves of (a, b) S. aureus, (c, d) E.
coli biofilms exposed to various concentrations (0.05 and 2 %) of either Mul-1867 or CHG for various durations (15, 30, and 60 s) are shown. The
antiseptic inhibitory effect on biofilms was assessed by measuring the number of CFU obtained after antibiotic treatment. All experiments were
performed in triplicates
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The amount of DNA was increased up to 4.5 times
following Mul-1867 treatment for 30 s compared to un-
treated cells.
Discussion
In this study, we examined the antibacterial activitiy of
both Mul-1867 and CHG against clinical isolates and
reference strains. We have shown that Mul-1867 had
broad-spectrum, fast-acting microbicidal activity. It seems
to act like other members of the polymeric guanidine fam-
ily targeting the membrane of the microorganisms [33].
In this study, Mul-1867 was shown to exhibit high
antimicrobial activity against all tested strains, including
MRSA, which were previously shown to respond poorly
to treatment with existing medicines [34, 35]. Import-
antly, we found that the MICs and MBC values of Mul-
1867 were less than 4 against a variety of gram-positive
bacteria, gram-negative bacteria, indicating that Mul-
1867 possesses bactericidal activity [28, 36]. Bactericidal
activity of Mul-1867 was confirmed by morphological
changes revealed by TEM suggested that the killing of
bacteria was the result of membrane disruption. It is
confirmed by an increased amount of DNA in the
medium 30 s after Mul-1867 treatment. The molecule of
Mul-1867 contains guanidine and hydrazine derivatives.
It is known that guanidines groups binds to negatively
charged molecules on bacterial surface like carboxyl
group (−COOH) of the fatty acid and hydrazine react
with carbonyl groups [37, 38]. Binding of guanidine and
hydrazine groups to phospholipids, cause bacterial death,
followed by disruption of the cell wall and consequent
bacteria lysis [39].
The main limitation of MIC and MBC measurements
is the inability of the method to determine the rate of
microbicidal activity. In our studies, we assessed bacter-
ial viability against Mul-1867 and CHG with time-kill
determinations [40]. This method determines the viabil-
ity of the organisms after contact with antimicrobials for
a specified time period and allows us to evaluate the ef-
fects of the potential antimicrobial on biofilms, which
play a significant role in numerous human diseases and
contribute to treatment inefficiency [41–43]. Time-kill
studies were performed with 48-h-old biofilms, and the
antimicrobial effects of both Mul-1867 and CHG were
determined using two commonly used chlorhexidine
concentrations [44, 45]. Time-kill curves of the isolates
have shown a clear relationship between the extent of
inhibition and the concentrations of Mul-1867 and
CHG, indicating that both compounds possessed dose-
dependent microbicidal activity and could be effective
within contact times starting at 15 s. Importantly, Mul-
1867 was up to 20 times more efficient than CHG at all
time points assessed.
Conclusions
Taken together, our data suggested that Mul-1867 is a
promising novel antimicrobial agent that has potent
broad-spectrum antibacterial activity against clinically
important microorganisms. Further studies will be di-
rected towards development of Mul-1867 as a locally
acting antimicrobial.
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Table 2 Effect of Mul-1867 on DNA release from bacteria
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S.aureus 0.062 0.279
Fig. 3 TEM micrographs of (a) untreated S.aureus (b) incubation with a 0.5 % Mul-1867 for 30 s shows some completely lysed cells
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